What does this research mean for the field?

Argon laser therapy significantly improves visual acuity and reduces subretinal fluid in patients with nonresolving central serous chorioretinopathy. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the outcomes of argon laser therapy for treating nonresolving central serous chorioretinopathy in a specific patient population.

March 14, 2026Delta Journal of OphthalmologyOpen Access

Argon laser photocoagulation therapy for nonresolving central serous chorioretinopathy

View Full Paper

Ask AI

Bookmark

Authors

IMIslam A. MohalhalResearch Institute of Ophthalmology AAAbdulaziz A. AlshamraniKing Fahd Medical City AAAbdukarim AlkharashiKing Saud Medical City

Discussion

Member takes

Implication

Case series shows significant visual improvement in Saudi patients with nonresolving CSCR after argon laser therapy, indicating its effectiveness.

Key Points

To evaluate the outcomes of argon laser therapy for treating nonresolving central serous chorioretinopathy in a specific patient population.
Prospective case series study of 20 eyes with nonresolving central serous chorioretinopathy.
Patients underwent thorough ocular assessments, including history, visual acuity, and imaging techniques.
Follow-up assessments were done for 6–30 months, with a mean of 9.7 months.
90% of patients improved with one laser session; 10% required two sessions.
Mean LogMAR visual acuity improved significantly from 0.51 to 0.23 after treatment.
Height of subretinal fluid decreased significantly from 196.79 µm to 11.16 µm post-treatment.

Cite This Study

Mohalhal et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc33b39f7826a300ce59 https://doi.org/10.4103/djo.djo_33_25

View Full Paper

Ask AI

Bookmark

March 14, 2026Delta Journal of OphthalmologyOpen Access

Argon laser photocoagulation therapy for nonresolving central serous chorioretinopathy

View Full Paper

Ask AI

Bookmark

Authors

IMIslam A. MohalhalResearch Institute of Ophthalmology AAAbdulaziz A. AlshamraniKing Fahd Medical City AAAbdukarim AlkharashiKing Saud Medical City

Discussion

Member takes

Implication

Case series shows significant visual improvement in Saudi patients with nonresolving CSCR after argon laser therapy, indicating its effectiveness.

Key Points

To evaluate the outcomes of argon laser therapy for treating nonresolving central serous chorioretinopathy in a specific patient population.
Prospective case series study of 20 eyes with nonresolving central serous chorioretinopathy.
Patients underwent thorough ocular assessments, including history, visual acuity, and imaging techniques.
Follow-up assessments were done for 6–30 months, with a mean of 9.7 months.
90% of patients improved with one laser session; 10% required two sessions.
Mean LogMAR visual acuity improved significantly from 0.51 to 0.23 after treatment.
Height of subretinal fluid decreased significantly from 196.79 µm to 11.16 µm post-treatment.

Cite This Study

Mohalhal et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc33b39f7826a300ce59 https://doi.org/10.4103/djo.djo_33_25

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark